SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

Video

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Related Videos
Related Content
Novavax’s Updated COVID-19 Vaccine is Granted EUL by WHO

Novavax’s Updated COVID-19 Vaccine is Granted EUL by WHO

December 2nd 2023
Article
Tailoring Therapies in Community Acquired Pneumonia in the Inpatient Setting

Tailoring Therapies in Community Acquired Pneumonia in the Inpatient Setting

November 6th 2023
Podcast
Merck's Adult Pneumococcal Vaccine Demonstrates ‘Superior Immunogenicity’

Merck's Adult Pneumococcal Vaccine Demonstrates ‘Superior Immunogenicity’

November 28th 2023
Article
Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

Vaccine Equality vs Equity with Dr. Jacinda Abdul-Mutakabbir

February 11th 2022
Podcast
Federal Agencies Work to Make RSV Monoclonal Antibody Immunization Accessible to Families

Federal Agencies Work to Make RSV Monoclonal Antibody Immunization Accessible to Families

November 18th 2023
Article
Can an Antiviral Reduce the Taste and Smell Disorder Associated With COVID-19?

Can an Antiviral Reduce the Taste and Smell Disorder Associated With COVID-19?

November 17th 2023
Article
© 2023 MJH Life Sciences

All rights reserved.